Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-desmethylclozapine
- Development stage
- Discontinued
- Lead developer
- Acadia Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
N-desmethylclozapine (NDMC), also known as ACP-104, is a small molecule and the primary active metabolite of the atypical antipsychotic clozapine. It is distinguished from its parent compound by its unique pharmacological profile, specifically acting as a partial agonist at the **muscarinic M1 receptor**, whereas clozapine acts as an antagonist. NDMC also functions as an agonist at the **5-HT1A receptor** and an antagonist at **5-HT2A**, **5-HT2C**, and **dopamine D2/D3 receptors**. The stimulation of M1 receptors by NDMC is hypothesized to enhance cognitive function by increasing the release of acetylcholine and dopamine in the prefrontal cortex, potentially addressing the cognitive deficits associated with schizophrenia. ACADIA Pharmaceuticals developed NDMC (as ACP-104) for the treatment of schizophrenia and related cognitive impairments, but clinical development was terminated following a Phase II trial that failed to meet its primary efficacy endpoints.
- Other names
- norclozapine
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2C (5-hydroxytryptamine 2C receptor)DRD2 (Dopamine D2 Receptor)M1 (Muscarinic acetylcholine receptor M1)CHRM4 (M4)DOR (Opioid Receptor Delta 1)HTR2A (Serotonin receptor 5-HT2A)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on N-desmethylclozapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-desmethylclozapine.